Can this biotech emerge from Mesoblast’s shadow?
Investors now have three ASX-listed stem cell therapy companies to choose from – and we can thank sector big daddy Mesoblast for inspiring the third.
Investors now have three ASX-listed stem cell therapy companies to choose from – and we can thank sector big daddy Mesoblast for inspiring the third.
In preparation for the transformation to gold producer, Besra Gold has brought two new directors onboard.
ClearVue Technologies partners up with one of New Zealand’s biggest glass manufactures to advance its proprietary technology.
Marking a key milestone in Queen Alexandra’s environmental permitting process, RC1 has begun flora and fauna studies.
Decidr AI Industries and Adisyn are among ASX technology companies reporting March quarterly results this week.
Here’s everything you need to know before the ASX opens today.
Stockhead’s Top 10 at 11, a short, sharp update to help frame the trading day.
Island Pharmaeuticals, Dimerix and Tryptamine Therapeutics are among ASX health stocks reporting quarterly results this week.
Dimerix has entered an exclusive licensing deal with Amicus Therapeutics to commercialise its phase III drug candidate DMX-200 in the US.
Good morning! Here’s everything you need to know, and some things you don’t, before the ASX flings open its doors and begins trading today.
ASX continues winning streak, Tesla quietly preps for life after Elon, and Andromeda hits ultra-pure alumina breakthrough.
Resolute Mining has scooped up two new, production ready gold projects in Côte d’Ivoire, Africa, from AngloGold.
The kidney drug developer has struck a partnering deal with a Nasdaq listed company that could deliver more than $1 billion in payments.
Harvest Technology Group updates on its last quarter, progress made on its three year plan and listing on the FSE.
Original URL: https://www.goldcoastbulletin.com.au/business/stockhead/page/46